Home > Dermatology > AAD 2020 > Pearls of the Posters > Selective IL-23 blocker safe in elderly psoriasis patients

Selective IL-23 blocker safe in elderly psoriasis patients

Presented By
Prof. Peter van de Kerkhof, Radboudumc, the Netherlands
Conference
AAD 2020
Trial
reSURFACE
A post-hoc analysis of the reSURFACE 1 and 2 trials showed that tildrakizumab is well tolerated in psoriasis patients >65 years [1]. Tildrakizumab is the second selective IL-23 blocker approved for treatment of patients with moderate-to-severe psoriasis. This was based on the positive results from the phase 3 reSURFACE trial that compared tildrakizumab with placebo and the TNF blocker etanercept. In this trial, tildrakizumab was well tolerated. However, elderly patients often suffer from cardiovascular comorbidity and are a particularly vulnerable group. Therefore, the current post-hoc analysis assessed the safety profile of tildrakizumab in elderly patients ≥65 years. Data for the analysis was derived from the phase 3 reSURFACE 1 (64 weeks) and reSURFACE 2 (52 weeks) tr...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on